Form 4: Altimmune CSO Exercises RSUs, Covers Taxes

Altimmune's Chief Scientific Officer, M Scot Roberts, exercised 14,600 Restricted Stock Units and subsequently sold 4,373 shares to cover tax obligations.

Summary

• M Scot Roberts, Chief Scientific Officer of Altimmune, Inc. (ALT), reported changes in beneficial ownership.
• On January 25, 2026, Roberts acquired 14,600 shares of Common Stock through the vesting of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, 4,373 shares of Common Stock were disposed of at a price of $5.5 per share to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Roberts directly beneficially owns 84,293 shares of Common Stock.
• Roberts also holds 29,200 derivative securities in the form of Restricted Stock Units.
• The RSUs vest in substantially equal annual installments over four years following January 25, 2024, contingent on continued service.

Sentiment

Score: 6

Explanation: The transaction is a routine vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. While a sale occurred, it was for tax purposes, and the executive continues to hold a significant number of shares and unvested RSUs, indicating continued alignment with the company's performance. This is generally viewed as a neutral to slightly positive event.

Positives

• The vesting of Restricted Stock Units indicates the executive's continued equity participation and alignment with shareholder interests.
• The transaction is a routine part of executive compensation, reflecting the successful vesting of previously granted awards.

Negatives

• A portion of the vested shares (4,373 shares) was sold to cover tax obligations, which reduces the executive's direct shareholding, though this is a standard practice.

Future Outlook

The filing indicates future vesting of the remaining 29,200 Restricted Stock Units in substantially equal annual installments over the period following January 25, 2024, subject to the reporting person's continued service.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, which is a common occurrence across all industries, particularly in biotechnology where equity-based compensation is prevalent.

Stakeholder Impact

• Shareholders: The transaction is a routine insider compensation event and is unlikely to have a significant direct impact on shareholders. It confirms the Chief Scientific Officer's ongoing equity stake in the company.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continued vesting of the remaining 29,200 Restricted Stock Units in annual installments, subject to M Scot Roberts' continued service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. Such transactions are common and typically pre-planned, reflecting standard executive compensation practices rather than a change in fundamental outlook or a strategic move. Therefore, this specific filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation.

Keywords

Altimmune, ALT, Form 4, Insider Transaction, Restricted Stock Units, RSU, M Scot Roberts, Chief Scientific Officer, Stock Vesting, Tax Withholding